Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial

American Journal of Transplantation

Volumn 16, Issue 11, 2016, Pages 3171-3180

  Strueber, M ^a   Warnecke, G ^b   Fuge, J ^b   Simon, A R ^c   Zhang, R ^b   Welte, T ^b   Haverich, A ^b   Gottlieb, J ^b  

^a Frederik Meijer Heart and Vascular Institute   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

antiproliferative agent: mycophenolate mofetil (MMF); bronchiolitis obliterans (BOS); calcineurin inhibitor: cyclosporine A (CsA); clinical research practice; clinical trial; immunosuppressant; immunosuppression immune modulation; lung transplantation pulmonology; mechanistic target of rapamycin (mTOR); pharmacology

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS; GANCICLOVIR; MYCOPHENOLATE MOFETIL; PREDNISOLONE; VALGANCICLOVIR; ANTINEOPLASTIC ANTIBIOTIC; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ABNORMAL LABORATORY RESULT; ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BRONCHIOLITIS OBLITERANS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY FUNCTION; LEUKOPENIA; LOWER RESPIRATORY TRACT INFECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBSTRUCTIVE AIRWAY DISEASE; OPEN STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; ADOLESCENT; COMPARATIVE STUDY; DRUG EFFECTS; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; LUNG DISEASES; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84992467141     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13835     Document Type: Article

References (29)

1. Maxwell BG, Levitt JE, Goldstein BA, et al. Impact of the lung allocation score on survival beyond 1 year. Am J Transplant 2014; 14: 2288–2294.
2. Glanville AR. CLAD: Does the Emperor have new clothes? Am J Transplant 2014; 14: 2681–2682.
3. Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med 2008; 177: 1033–1040.
4. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: A UK Registry audit. Am J Transplant 2010; 10: 1889–1896.
5. Hausen B, Gummert J, Berry GJ, et al. Prevention of acute allograft rejection in nonhuman primate lung tranplant recipients: Induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Transplantation 2000; 69: 488–496.
6. Neumayer HH, Paradis K, Korn A, et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 1999; 48: 694–703.
7. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847–858.
8. Snell GI, Valentine VG, Vitulo P, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: An international, randomized, double-blind clinical trial. Am J Transplant 2006; 6: 169–177.
9. Bhorade S, Ahya VN, Baz MA, et al. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. Am J Respir Crit Care Med 2011; 183: 379–387.
10. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297–310.
11. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319–338.
12. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229–1242.
13. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.
14. Glanville AR, Aboyoun C, Klepetko W, et al. Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation. J Heart Lung Transplant 2015; 34: 16–25.
15. Lovric S, Kielstein JT, Kayser D, et al. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients—A case series. Nephrol Dial Transplant 2011; 26: 3032–3038.
16. Treede H, Glanville AR, Klepetko W, et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant 2012; 31: 797–804.
17. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234–1248.
18. Ghassemieh B, Ahya VN, Baz MA, et al. Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation. J Heart Lung Transplant 2013; 32: 701–706.
19. Struijk GH, Minnee RC, Koch SD, et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney Int 2010; 78: 934–940.
20. Wiita AP, Roubinian N, Khan Y, et al. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transpl Infect Dis 2012; 14: 248–258.
21. Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant 2006; 6: 671–679.
22. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-seventh official adult lung and heart-lung transplant report—2010. J Heart Lung Transplant 2010; 29: 1104–1118.
23. Glanville AR, Morton JM, Aboyoun CL, Plit ML, Malouf MA. Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation. J Heart Lung Transplant 2004; 23: 1170–1174.
24. Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of Neoral C(2) monitoring: A review. Transplantation 2002; 73(9 Suppl): S3–S11.
25. Iversen M, Nilsson F, Sipponen J, et al. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: The NOCTURNE study. J Heart Lung Transplant 2009; 28: 919–926.
26. Schneer S, Kramer MR, Fox B, et al. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant. Clin Transplant 2014; 28: 662–668.
27. Gullestad L, Iversen M, Mortensen SA, et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: A multicenter, randomized trial. Transplantation 2010; 89: 864–872.
28. Arora S, Gude E, Sigurdardottir V, et al. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: The significance of baseline glomerular filtration rate. J Heart Lung Transplant 2012; 31: 259–265.
29. Shaffi K, Uhlig K, Perrone RD, et al. Performance of creatinine-based GFR estimating equations in solid-organ transplant recipients. Am J Kidney Dis 2014; 63: 1007–1018.